NEXGEL, Inc.
NASDAQ Capital MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Brian J. Kieser
- Full Time Employees
- 19
- Sector
- Healthcare
- Industry
- Medical - Instruments & Supplies
- Address
- 2150 Cabot Boulevard West Langhorne PA United States of America 19047
- IPO Date
- Dec 22, 2021
- CIK
- 0001468929
- Website
- nexgel.com
- Similar Companies
- Business
- NEXGEL, Inc. (NasdaqCM: NXGL) develops, manufactures, and markets hydrogel-based consumer and medical products. The company offers a range of topical pain relief products under the NEXGEL Pain Relief brand, including creams, gels, and patches formulated with natural ingredients such as arnica and menthol for targeted relief from muscle aches, joint pain, and inflammation; advanced wound care solutions like SILVAGEL, an antimicrobial hydrogel dressing for burns and chronic wounds; and specialty medical hydrogels used in incontinence care, burn treatment, and veterinary applications. Its product portfolio also encompasses custom hydrogel formulations for contract manufacturing partners in the pharmaceutical and consumer health sectors, serving healthcare providers, retailers, and direct-to-consumer channels primarily in North America. Founded in 2003 and headquartered in Lawrenceville, New Jersey, NEXGEL operates within the healthcare and consumer products industry, focusing on segments such as over-the-counter pain management, wound care, and biomedical materials, with distribution through e-commerce, major retailers, and medical supply networks. In the past two years, NEXGEL has pursued strategic expansions including a distribution partnership with a leading national pharmacy chain to broaden retail availability of its pain relief line, a funding round in 2024 that supported production scaling and new product R&D, and the launch of an enhanced arnica-based gel variant targeting sports recovery markets.
Company News
NEXGEL, Inc. (NXGL) Discusses Strategic Platform Reorganization and Refocus on Medical Device and Biomedical Innovation Transcript
NEXGEL Announces Dial-In Details for Investor Update Call
NEXGEL Announces Date for Investor Update Call
NEXGEL ANNOUNCES LEADERSHIP TRANSITION AND STRATEGIC REVIEW INITIATIVE
NEXGEL Reports Second Quarter 2026 Financial Results
NEXGEL to Present at Planet MicroCap Conference Las Vegas on June 16th –18th
NEXGEL Reports Positive Data from Randomized Single-Center IRB Study to Evaluate the Effectiveness and Safety of a Hydrogel Laser Treatment Patch in Laser Hair Removal with a 95.6% Reduction in Plume Concentration
NEXGEL, Inc. (NXGL) Q1 2026 Earnings Call Transcript
NEXGEL Appoints Dave Hazard as Vice President of Sales for BIONX Surgical
NEXGEL To Report First Quarter 2026 Financial Results on May 15th
NEXGEL To Report First Quarter 2026 Financial Results on May 15th
NEXGEL Appoints Brian Kieser and Kevin Harris from New Strategic Partner, Sequence LifeScience™, to Board of Directors
NEXGEL Appoints Ian Blackman as Chief Financial Officer
NexGel Calls Celularity Wound Deal “Transformational,” Eyes $35M Revenue and EBITDA Profitability
NEXGEL, Inc. (NXGL) Q4 2025 Earnings Call Transcript
NEXGEL New Strategic Partner, Sequence LifeScience™, Leads Financing with $5.5 Million to Complete Acquisition of Celularity Degenerative Disease Segment
Financial Comparison: NexGel (NASDAQ:NXGL) and Pressure BioSciences (OTCMKTS:PBIO)
NEXGEL Moves Forward Shareholder Update Call to Discuss Celularity Transaction on April 21st at 4:30 P.M. ET
NEXGEL Reschedules Shareholder Update Conference Call to April 23rd at 4:30 P.M. ET to Provide Update on Celularity Transaction
NEXGEL Reschedules Shareholder Update Conference Call to April 15th at 4:30 P.M. ET to Provide Update on Celularity Transaction